VEGFA and endophthalmitis: Despite these events, no other complications such as anterior chamber reaction or endophthalmitis were noted in this study regardless of the previously reported association of dexamethasone phosphate and a higher rate of endophthalmitis than with anti-VEGF agents (0.13% X 0.019%, respectively) [32].